Search results
AstraZeneca posts mixed results from recent Imfinzi trials
ShareCast· 4 days agoAstraZeneca announced contrasting results from two phase three trials involving its immunotherapy...
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
Zacks via Yahoo Finance UK· 1 day agoThis Score examines things like projected and historical earnings, sales, and cash flow to find...
AstraZeneca disappointed with failure of immunotherapy in early-stage lung cancer
Proactive Financial News· 4 days agoAstraZeneca PLC (LSE:AZN) shared some disappointing news on an advanced lung cancer trial of its...
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Zacks via Yahoo Finance UK· 3 days agoData from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy...
Google Deepmind among nominees for ‘Nobel Prize of engineering’
CityAM via Yahoo Finance UK· 1 day agoAI-powered weather forecasting, innovative heat batteries and the rapid manufacturing scale-up of a...
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
Zacks via Yahoo Finance UK· 1 day agoThis week, the FDA rejected Merck's MRK and AbbVie’s ABBV regulatory filings seeking approvals for...
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment
Reuters· 3 days agoAstraZeneca said the approval by China's National Medical Products Administration (NMPA) was based...
AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung...
Benzinga via Yahoo Finance UK· 4 days agoOn Tuesday, AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADJUVANT BR.31 Phase 3...
AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers
Reuters via Yahoo Finance UK· 4 days agoImfinzi is a human monoclonal antibody, which works to block a tumour's ability to evade and dampen...
TOP NEWS: AstraZeneca details mixed findings from cancer drug trials
Morningstar· 4 days agoShares in AstraZeneca rose 0.6% to 12,548.00 pence on Tuesday morning. The Cambridge-based pharmaceutical company said Imfinzi met both its primary and secondary aims in a trial on sufferers of bladder cancer.